Pilot study on the therapeutic efficacy, clinical safety, and dosage finding of enciprazine in out-patients with anxious and anxious-depressive syndromes.
The new basic propanolamine derivative enciprazine (D 13 112) was tested in an open single-blind phase-II trial with regard to therapeutic efficacy, clinical safety, and dosage finding. The drug showed a good efficacy in mildly ill patients. Under the highest dosage frequently fatigue was reported. In 78% of the patients the enciprazine trial succeeded in shifting patients from benzodiazepines to non-benzodiazepines or in discontinuation of psychopharmacotherapy after completion of the trial.
Scheibe
G
G
Psychiatric Hospital, University of Munich, Fed. Rep. of Germany.
Grohmann
R
R
Buchheim
P
P
D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010865:Pilot Projects; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales; D016037:Single-Blind Method; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D010879:Piperazines; D014149:Tranquilizing Agents; D011388:Prolactin; C057238:enciprazine